Cabozantinib improves survival in patients with advanced kidney cancer: Results from the METEOR trial

Patients with advanced kidney cancer live for nearly twice as long without their disease progressing if they are treated with cabozantinib, a drug that inhibits the action of tyrosine kinases -- enzymes that function as an 'on' or 'off' switch in many cellular processes, including cancer. The research will be presented in the presidential session of the 2015 European Cancer Congress on Saturday.